Terrance Mcguire Sells 119,805 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 119,805 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10. Following the sale, the director now directly owns 3,568,274 shares of the company's stock, valued at approximately $1,498,675.08. The trade was a 3.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total value of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total value of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

Shares of Invivyd stock traded up $0.02 during trading on Thursday, hitting $0.53. 870,708 shares of the stock were exchanged, compared to its average volume of 667,876. The stock's fifty day moving average is $0.74 and its 200 day moving average is $0.99. The stock has a market cap of $63.44 million, a PE ratio of -0.27 and a beta of 0.53. Invivyd, Inc. has a 12 month low of $0.40 and a 12 month high of $5.20.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IVVD. HC Wainwright decreased their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a report on Wednesday, November 20th. Finally, D. Boral Capital reiterated a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $7.89.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new stake in Invivyd during the 3rd quarter valued at $27,000. XTX Topco Ltd lifted its holdings in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after purchasing an additional 15,376 shares during the period. SG Americas Securities LLC grew its position in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock valued at $42,000 after buying an additional 25,201 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd during the 2nd quarter valued at about $86,000. Finally, Rhumbline Advisers lifted its stake in shares of Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock worth $92,000 after acquiring an additional 82,164 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.